{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:09Z","timestamp":1786982769905,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40265-024-02016-5","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T02:01:52Z","timestamp":1711764112000},"page":"441-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease"],"prefix":"10.1007","volume":"84","author":[{"given":"Amy","family":"Zhuang-Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"issue":"3","key":"2016_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276\u201383.","journal-title":"Ocul Surf"},{"issue":"3","key":"2016_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575\u2013628.","journal-title":"Ocul Surf"},{"issue":"3","key":"2016_CR3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","volume":"12","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12(3):1397\u2013418.","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"2016_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334\u201365.","journal-title":"Ocul Surf"},{"issue":"2","key":"2016_CR5","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3390\/ijerph20021313","volume":"20","author":"D Wrobel-Dudzinska","year":"2023","unstructured":"Wrobel-Dudzinska D, Osial N, Stepien PW, et al. Prevalence of dry eye symptoms and associated risk factors among university students in Poland. Int J Environ Res Public Health. 2023;20(2):1313.","journal-title":"Int J Environ Res Public Health"},{"issue":"17","key":"2016_CR6","first-page":"8642","volume":"24","author":"S Barabino","year":"2020","unstructured":"Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020;24(17):8642\u201352.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"2016_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.survophthal.2019.08.007","volume":"65","author":"S Sabeti","year":"2020","unstructured":"Sabeti S, Kheirkhah A, Yin J, et al. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020;65(2):205\u201317.","journal-title":"Surv Ophthalmol"},{"key":"2016_CR8","unstructured":"Mukamal R. Improved dry eye drugs for 2022 and beyond. 2021. https:\/\/www.aao.org\/eye-health\/tips-prevention\/new-dry-eye-treatments-ocular-surface-disease. Accessed 27 Feb 2024."},{"key":"2016_CR9","unstructured":"US Food and Drug Administration. MIEBO (perfluorohexyloctane ophthalmic solution) for topical ophthalmic use: US prescribing information. 2024. https:\/\/dailymed.nlm.nih.gov\/dailymed. Accessed 27 Feb 2024."},{"issue":"1\u20132","key":"2016_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","volume":"538","author":"P Agarwal","year":"2018","unstructured":"Agarwal P, Scherer D, G\u00fcnther B, et al. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm. 2018;538(1\u20132):119\u201329.","journal-title":"Int J Pharm"},{"issue":"4","key":"2016_CR11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/pharmaceutics15041211","volume":"15","author":"C Tsagogiorgas","year":"2023","unstructured":"Tsagogiorgas C, Otto M. Semifluorinated alkanes as new drug carriers-an overview of potential medical and clinical applications. Pharmaceutics. 2023;15(4):1211.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2016_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/ICO.0000000000002622","volume":"40","author":"J Tauber","year":"2021","unstructured":"Tauber J, Wirta DL, Sall K, et al. A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea. 2021;40(9):1132\u201340.","journal-title":"Cornea"},{"issue":"5","key":"2016_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1246\/bcsj.20170431","volume":"91","author":"X Liu","year":"2018","unstructured":"Liu X, Riess J, Krafft M. Self-organization of semifluorinated alkanes and related compounds at interfaces: thin films, surface domains and two-dimensional spherulites. Bull Chem Soc Jpn. 2018;91(5):846\u201357.","journal-title":"Bull Chem Soc Jpn"},{"key":"2016_CR14","unstructured":"Kr\u00f6sser S, Spencer E, Grillenberger R, et al. Ocular and systemic distribution of 14C- perfluorohexyloctane following topical ocular administration to rabbits [abstract no. 2656 plus poster]. Invest Ophthalmol Vis Sci. 2018;59(9):2656."},{"issue":"3","key":"2016_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/jop.2019.0092","volume":"36","author":"D Schmidl","year":"2020","unstructured":"Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154\u201361.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9","key":"2016_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1089\/jop.2017.0042","volume":"33","author":"P Steven","year":"2017","unstructured":"Steven P, Augustin AJ, Geerling G, et al. Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease. J Ocul Pharmacol Ther. 2017;33(9):678\u201385.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2016_CR17","doi-asserted-by":"crossref","unstructured":"Borchman D, Vittitow J, Kissling R, et al. Spectroscopic characterization of perfluorohexyloctane, an eye drop for dry eye disease [abstract no. 3975-B0292 plus poster]. Invest Ophthalmol Vis Sci. 2023;64(8):3975.","DOI":"10.1016\/j.curtheres.2023.100704"},{"issue":"100705","key":"2016_CR18","first-page":"1","volume":"98","author":"N Stolowich","year":"2023","unstructured":"Stolowich N, Vittitow J, Kissling R, et al. Oxygen-carrying capacity of perfluorohexyloctane, a novel eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98(100705):1\u20135.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"2016_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jtos.2019.02.010","volume":"17","author":"P Agarwal","year":"2019","unstructured":"Agarwal P, Khun D, Kr\u00f6sser S, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. Ocul Surf. 2019;17(2):241\u20139.","journal-title":"Ocul Surf"},{"issue":"8","key":"2016_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/jop.2015.0048","volume":"31","author":"P Steven","year":"2015","unstructured":"Steven P, Scherer D, Kr\u00f6sser S, et al. Semifluorinated alkane eye drops for treatment of dry eye disease-a prospective, multicenter noninterventional study. J Ocul Pharmacol Ther. 2015;31(8):498\u2013503.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"100704","key":"2016_CR21","first-page":"1","volume":"98","author":"J Vittitow","year":"2023","unstructured":"Vittitow J, Kissling R, DeCory H, et al. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98(100704):1\u20137.","journal-title":"Curr Ther Res Clin Exp"},{"key":"2016_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.709712","volume":"8","author":"M Delicado-Miralles","year":"2021","unstructured":"Delicado-Miralles M, Velasco E, D\u00edaz-Tahoces A, et al. Deciphering the action of perfluorohexyloctane eye drops to reduce ocular discomfort and pain. Front Med (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fmed.2021.709712.","journal-title":"Front Med (Lausanne)."},{"key":"2016_CR23","unstructured":"Borchman D, Cavet M, DeCory H, et al. Visualization of perfluorohexyloctane, an eye drop for dry eye disease, on the human ocular surface using infrared emissivity [poster]. Annual meeting of the American Academy of Ophthalmology. 2023."},{"issue":"5","key":"2016_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","volume":"130","author":"J Tauber","year":"2023","unstructured":"Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516\u201324.","journal-title":"Ophthalmology"},{"key":"2016_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","volume":"252","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Kurata F, Epitropoulos AT, et al. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023;252:265\u201374.","journal-title":"Am J Ophthalmol"},{"key":"2016_CR26","doi-asserted-by":"publisher","unstructured":"Protzko EE, Segal BA, Korenfeld MS, et al. Long-term safety and efficacy of perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the KALAHARI Study. Cornea. 2023. https:\/\/doi.org\/10.1097\/ICO.0000000000003418.","DOI":"10.1097\/ICO.0000000000003418"},{"key":"2016_CR27","unstructured":"Fahmy A, Evans D, Harthan J, et al. Perfluorohexyloctane (NOV03) for dry eye disease associated with meibomian gland dysfunction: pooled analysis of GOBI and MOJAVE studies [poster]. Annual Meeting of the American Optometric Association. 2023."},{"issue":"6","key":"2016_CR28","first-page":"32","volume":"12","author":"D Gro\u00df","year":"2021","unstructured":"Gro\u00df D, Kaercher T. Comparison of the clinical efficacy of three different eye drops for the treatment of dry eye. EC Ophthalmol. 2021;12(6):32\u201344.","journal-title":"EC Ophthalmol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02016-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:39:47Z","timestamp":1715989187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02016-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02016-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"assertion":[{"value":"27 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Amy Zhuang-Yan and Yahiya Y. Syed are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}